NIH-funded research R21 grant

How different types of interferons help protect against respiratory viruses

Official title: Interplay between canonical and non-canonical interferons in defense against respiratory viruses

Funded at Yale University · NIH-11119021 · Data updated 2026-11-12

This study is looking at how a special protein called IFN epsilon helps protect our lungs from viruses like COVID-19 and the flu, and it hopes to find new ways to improve treatments for asthma and other lung issues.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionYale University
NIH-funded
Lab location1 site (New Haven, United States)
Project startJune 17, 2024
Project endApril 30, 2026
Funding year2025
Award (this year)$209,375
NIH project number5R21AI182621-02
Project IDNIH-11119021 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research include individuals with respiratory conditions such as asthma or COPD, as well as those who have been affected by respiratory viruses.

Less likely to help

Patients with non-respiratory conditions or those who do not have a history of respiratory viral infections may not benefit from this research.

What this research studies

This research investigates the role of various interferons, particularly a lesser-known type called IFN epsilon, in defending the respiratory system against viruses like SARS-CoV-2 and influenza. It aims to understand how these interferons are produced in the airway and how they can stimulate antiviral responses. By studying the balance between different interferons, the research seeks to uncover new insights into how the body responds to respiratory infections and the potential implications for treating conditions like asthma and chronic lung disease.

Why it matters

Potential benefit: If successful, this research could lead to improved treatments for respiratory viral infections and better management of chronic lung diseases.

How similar studies have gone: While the role of canonical interferons is well-established, the investigation of IFN epsilon in the respiratory tract is relatively novel and has not been extensively studied.

Where this research is happening

  • Yale University
    New Haven, United States
    Active

Researchers

  • Principal investigator: Foxman, Ellen Flescher — Yale University
  • Study coordinator: Foxman, Ellen Flescher

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.